Preventing atherosclerosis with angiotensin-converting enzyme inhibitors: Emphasis on diabetic atherosclerosis

Current Drug Targets - Cardiovascular and Haematological Disorders

Volumn 5, Issue 6, 2005, Pages 503-512

  Allen, Terri J ^a   Jandeleit Dahm, K A ^a  

^a BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

Author keywords

ACE inhibitors; Atherosclerosis; Diabetes; Plaque; Renin angiotensin system

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ALPHA TOCOPHEROL; AMLODIPINE; ANGIOTENSIN; ANGIOTENSIN RECEPTOR ANTAGONIST; ATENOLOL; CALCIUM CHANNEL BLOCKING AGENT; CANDESARTAN; CAPTOPRIL; CHLORTALIDONE; CYTOKINE; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; FOSINOPRIL; GROWTH FACTOR; HYDROCHLOROTHIAZIDE; LISINOPRIL; METOPROLOL; PERINDOPRIL; PLATELET DERIVED GROWTH FACTOR; QUINAPRIL; RAMIPRIL; SIMVASTATIN; STREPTOKINASE; TELMISARTAN; TRANDOLAPRIL; UNINDEXED DRUG; VASCULOTROPIN;

ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE MARKER; DISEASE MODEL; DRUG EFFICACY; DRUG MECHANISM; DYSLIPIDEMIA; ENDOTHELIUM LESION; ENZYME INHIBITION; HEART INFARCTION; HUMAN; HYPERTENSION; INCIDENCE; LIFESTYLE; METABOLIC DISORDER; NONHUMAN; OBESITY; OXIDATIVE STRESS; PATHOGENESIS; PRIMARY PREVENTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK ASSESSMENT;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; ATHEROSCLEROSIS; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; HUMANS;

EID: 29444436800     PISSN: 15680061     EISSN: None     Source Type: Journal    
DOI: 10.2174/156800605774962068     Document Type: Review

References (98)

1. Haffner, S.M., Lehto, S., Ronnemaa, T., Pyorala, K., Laakso, M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N. Engl. J. Med., 1998, 339, 229-234.
2. Cooper, M.E., Johnston, C.I. Optimizing treatment of hypertension in patients with diabetes. JAMA, 2000, 283, 3177-3179.
3. Stamler, J., Vaccaro, O., Neaton, J.D., Wentworth, D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabet. Care, 1993, 16, 434-444.
4. Kannel, W.B., McGee, D.L. Diabetes and cardiovascular risk factors: the Framingham study. Circulation, 1979, 59, 8-13.
5. Laing, S.P., Swerdlow, A.J., Slater, S.D., Burden, A.C., Morris, A., Waugh, N.R., Gatling, W., Bingley, P.J., Patterson, C.C. Mortality from heart disease in a cohort of 23,000 patients with insulin-treated diabetes. Diabetologia, 2003, 46, 760-765.
6. Laing, S.P., Swerdlow, A.J., Carpenter, L.M., Slater, S.D., Burden, A.C., Botha, J.L., Morris, A.D., Waugh, N.R., Gatling, W., Gale, E.A., Patterson, C.C., Qiao, Z., Keen, H. Mortality from cerebrovascular disease in a cohort of 23 000 patients with insulin-treated diabetes. Stroke, 2003, 34, 418-421.
7. Starkman, H.S., Cable, G., Hala, V., Hecht, H., Donnelly, C.M. Delineation of prevalence and risk factors for early coronary artery disease by electron beam computed tomography in young adults with type 1 diabetes. Diabet. Care, 2003, 26, 433-436.
8. Maher, J.E., Raz, J.A., Bielak, L.F., Sheedy, P.F. 2nd., Schwartz, R.S., Peyser, P.A. Potential of quantity of coronary artery calcification to identify new risk factors for asymptomatic atherosclerosis. Am. J. Epidemiol., 1996, 144, 943-953.
9. Nathan, D.M., Lachin, J., Cleary, P., Orchard, T., Brillon, D.J., Backlund, J.Y., O'Leary, D.H., Genuth, S. Intensive diabetes therapy and carotid intima-media thickness in type 1 diabetes mellitus. N. Engl. J. Med., 2003, 348, 2294-2303.
10. Uusitupa, M.I., Niskanen, L.K., Siitonen, O., Voutilainen, E., Pyorala, K. 5-year incidence of atherosclerotic vascular disease in relation to general risk factors, insulin level, and abnormalities in lipoprotein composition in non-insulin-dependent diabetic and nondiabetic subjects. Circulation, 1990, 82, 27-36.
11. Moreno, P.R., Murcia, A.M., Palacios, I.F., Leon, M.N., Bernardi, V.H., Fuster, V., Fallon, J.T. Coronary composition and macrophage infiltration in atherectomy specimens from patients with diabetes mellitus. Circulation, 2000, 102, 2180-2184.
12. Burke, A.P., Kolodgie, F.D., Zieske, A., Fowler, D.R., Weber, D.K., Varghese, P.J., Farb, A., Virmani, R. Morphologic findings of coronary atherosclerotic plaques in diabetics: a postmortem study. Arterioscler. Thromb. Vasc. Biol., 2004, 24, 1266-1271.
13. Duff, G.L., Brechin, D.J., Finkelstein, W.E. The effect of alloxan diabetes on experimental cholesterol atherosclerosis in the rabbit. IV. The effect of insulin therapy on the inhibition of atherosclerosis in the alloxan-diabetic rabbit. J. Exp. Med., 1954, 100, 371-380.
14. Reardon, C.A., Getz, G.S. Mouse models of atherosclerosis. Curr. Opin. Lipidol., 2001, 12, 167-173.
15. Nakashima, Y., Plump, A.S., Raines, E.W., Breslow, J.L., Ross, R. ApoE-deficient mice develop lesions of all phases of atherosclerosis throughout the arterial tree. Arterioscler. Thromb., 1994, 14, 133-140.
16. Park, L., Raman, K.G., Lee, K.J., Lu, Y., Ferran, L.J. Jr., Chow, W.S., Stern, D., Schmidt, A.M. Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts. Nat. Med., 1998, 4, 1025-1031.
17. Candido, R., Jandeleit-Dahm, K.A., Cao, Z., Nesteroff, S.P., Burns, W.C., Twigg, S.M., Dilley, R.J., Cooper, M.E., Allen, T.J. Prevention of accelerated atherosclerosis by angiotensin-converting enzyme inhibition in diabetic apolipoprotein E-deficient mice. Circulation, 2002, 106, 246-253.
18. Candido, R., Allen, T.J., Lassila, M., Cao, Z., Thallas, V., Cooper, M.E., Jandeleit-Dahm, K.A. Irbesartan but not amlodipine suppresses diabetes-associated atherosclerosis. Circulation, 2004, 109, 1536-1542.
19. Kako, Y., Masse, M., Huang, L.S., Tall, A.R., Goldberg, I.J. Lipoprotein lipase deficiency and CETP in streptozotocin-treated apoB-expressing mice. J. Lipid Res., 2002, 43, 872-877.
20. Keren, P., George, J., Shaish, A., Levkovitz, H., Janakovic, Z., Afek, A., Goldberg, I., Kopolovic, J., Keren, G., Harats, D. Effect of hyperglycemia and hyperlipidemia on atherosclerosis in LDL receptor-deficient mice: establishment of a combined model and association with heat shock protein 65 immunity. Diabetes, 2000, 49, 1064-1069.
21. Hasty, A.H., Shimano, H., Osuga, J., Namatame, I., Takahashi, A., Yahagi, N., Perrey, S., Iizuka, Y., Tamura, Y., Amemiya-Kudo, M., Yoshikawa, T., Okazaki, H., Ohashi, K., Harada, K., Matsuzaka, T., Sone, H., Gotoda, T., Nagai, R., Ishibashi, S., Yamada, N. Severe hypercholesterolemia, hypertriglyceridemia, and atherosclerosis in mice lacking both leptin and the low density lipoprotein receptor. J. Biol. Chem., 2001, 276, 37402-7408.
22. Renard, C.B., Kramer, F., Johansson, F., Lamharzi, N., Tannock, LR., von Herrath, M.G., Chait, A., Bornfeldt, K.E. Diabetes and diabetes-associated lipid abnormalities have distinct effects on initiation and progression of atherosclerotic lesions. J. Clin. Invest., 2004, 114, 659-668.
23. Anderson, T.J., Uehata, A., Gerhard, M.D., Meredith, I.T., Knab, S., Delagrange, D., Lieberman, E.H., Ganz, P., Creager, M.A., Yeung, A.C. et al. Close relation of endothelial function in the human coronary and peripheral circulations. J. Am. Coll. Cardiol., 1995, 26, 1235-1241.
24. Takase, B., Uehata, A., Akima, T., Nagai, T., Nishioka, T., Hamabe, A., Satomura, K., Ohsuzu, F., Kurita, A. Endothelium-dependent flow-mediated vasodilation in coronary and brachial arteries in suspected coronary artery disease. Am. J. Cardiol., 1998, 82, 1535-1539, A1537-1538.
25. Burke, G.L., Evans, G.W., Riley, W.A., Sharrett, A.R., Howard, G., Barnes, R.W., Rosamond, W., Crow, R.S., Rautaharju, P.M., Heiss, G. Arterial wall thickness is associated with prevalent cardiovascular disease in middle-aged adults. The Atherosclerosis Risk in Communities (ARIC) Study. Stroke, 1995, 26, 386-391.
26. Cameron, J.D., Jennings, G.L., Dart, A.M. Systemic arterial compliance is decreased in newly-diagnosed patients with coronary heart disease: implications for prediction of risk. J. Cardiovasc. Risk, 1996, 3, 495-500.
27. Blacher, J., Asmar, R., Djane, S., London, G.M., Safar, M.E. Aortic pulse wave velocity as a marker of cardiovascular risk in hypertensive patients. Hypertension, 1999, 33, 1111-1117.
28. Szmitko, P.E., Wang, C.H., Weisel, R.D., Jeffries, G.A., Anderson, T.J., Verma, S. Biomarkers of vascular disease linking inflammation to endothelial activation: Part II. Circulation, 2003, 108, 2041-2048.
29. Mehta, J.L., Li, D. Identification, regulation and function of a novel lectin-like oxidized low-density lipoprotein receptor. J. Am. Coll. Cordiol., 2002, 39, 1429-1435.
30. Galis, Z.S., Khatri, J.J. Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly. Circ. Res., 2002, 90, 251-262.
31. Galis, Z.S., Sukhova, G.K., Lark, M.W., Libby, P. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J. Clin. Invest., 1994, 94, 2493-2503.
32. Marx, N., Froehlich, J., Siam, L., Ittner, J., Wierse, G., Schmidt, A., Scharnagl, H., Hombach, V., Koenig, W. Antidiabetic PPAR gamma-activator rosiglitazone reduces MMP-9 serum levels in type 2 diabetic patients with coronary artery disease. Arterioscler. Thromb. Vasc. Biol., 2003, 23, 283-288.
33. Coughlin, S.R. Thrombin signalling and protease-activated receptors. Nature, 2000, 407, 258-264.
34. Coughlin, S.R., Camerer, E. PARticipation in inflammation. J. Clin. Invest., 2003, 111, 25-27.
35. Cheung, W.M., D'Andrea, M.R., Andrade-Gordon, P., Damiano, B.P. Altered vascular injury responses in mice deficient in protease-activated receptor-1. Arterioscler. Thromb. Vasc. Biol., 1999, 19, 3014-3024.
36. Poulsen, P.L., Hansen, K.W., Mogensen, C.E. Ambulatory blood pressure in the transition from normo- to microalbuminuria. A longitudinal study in IDDM patients. Diabetes, 1994, 43, 1248-1253.
37. Hypertension in Diabetes Study (HDS): I. Prevalence of hypertension in newly presenting type 2 diabetic patients and the association with risk factors for cardiovascular and diabetic complications. J. Hypertens., 1993, 11, 309-317.
38. Turner, R.C., Millns, H., Neil, H.A., Stratton, I.M., Manley, S.E., Matthews, D.R., Holman, R.R. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus: United Kingdom Prospective Diabetes Study (UKPDS: 23). BMJ, 1998, 316, 823-828.
39. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. BMJ, 1998, 317, 703-713.
40. Potter, D.D., Sobey, C.G., Tompkins, P.K., Rossen, J.D., Heistad, D.D. Evidence that macrophages in atherosclerotic lesions contain angiotensin II. Circulation, 1998, 98, 800-807.
41. Diet, F., Pratt, R.E., Berry, G.J., Momose, N., Gibbons, G.H., Dzau, V.J. Increased accumulation of tissue ACE in human atherosclerotic coronary artery disease. Circulation, 1996, 94, 2756-2767.
42. Weiss, D., Kools, J.J., Taylor, W.R. Angiotensin II-induced hypertension accelerates the development of atherosclerosis in apoE-deficient mice. Circulation, 2001, 103, 448-454.
43. Lonn, E. Antiatherosclerotic effects of ACE inhibitors: where are we now? Am. J. Cardiovasc. Drugs, 2001, 1, 315-320.
44. Miyata, T., van Ypersele de Strihou, C., Ueda, Y., Ichimori, K., Inagi, R., Onogi, H., Ishikawa, N., Nangaku, M., Kurokawa, K. Angiotensin II receptor antagonists and angiotensin-converting enzyme inhibitors lower in vitro the formation of advanced glycation end products: biochemical mechanisms. J. Am. Soc. Nephrol., 2002, 13, 2478-2487.
45. Chobanian, A.V., Haudenschild, C.C., Nickerson, C., Drago, R. Antiatherogenic effect of captopril in the Watanabe heritable hyperlipidemic rabbit. Hypertension, 1990, 15, 327-331.
46. Aberg, G., Ferrer, P. Effects of captopril on atherosclerosis in cynomolgus monkeys. J. Cardiovasc. Pharmacol., 1990, 15 (Suppl. 5), S65-72.
47. Hoshida, S., Nishida, M., Yamashita, N., Igarashi, J., Aoki, K., Hori, M., Kuzuya, T., Tada, M. Vascular angiotensin-converting enzyme activity in cholesterol-fed rabbits: effects of enalapril. Atherosclerosis, 1997, 130, 53-59.
48. Rolland, P.H., Charpiot, P., Friggi, A., Piquet, P., Barlatier, A., Scalbert, E., Bodard, H., Tranier, P., Mercier, C., Luccioni, R. et al. Effects of angiotensin-converting enzyme inhibition with perindopril on hemodynamics, arterial structure, and wall rheology in the hindquarters of atherosclerotic mini-pigs. Am. J. Cardiol., 1993, 71, 22E-27E.
49. Lucas, A., Dai, E., Liu, L.Y., Nation, P.N. Atherosclerosis in Marek's disease virus infected hypercholesterolemic roosters is reduced by HMGCoA reductase and ACE inhibitor therapy. Cardiovasc. Res., 1998, 38, 237-246.
50. Jandeleit-Dahm, K., Cooper, M.E. Hypertension and diabetes. Curr. Opin. Nephrol. Hypertens., 2002, 11, 221-228.
51. Chobanian, A.V., Bakris, G.L., Black, H.R., Cushman, W.C., Green, L.A., Izzo, J.L. Jr., Jones, D.W., Materson, B.J., Oparil, S., Wright, J.T. Jr., Roccella, E.J. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA, 2003, 289, 2560-2572.
52. Unger, T. The ongoing telmisartan alone and in combination with ramipril global endpoint trial program. Am. J. Cardiol., 2003, 91, 28G-34G.
53. Mancini, G.B., Henry, G.C., Macaya, C., O'Neill, B.J., Pucillo, A.L., Carere, R.G., Wargovich, T.J., Mudra, H., Luscher, T.F., Klibaner, M.I., Haber, H.E., Uprichard, A.C., Pepine, C.J., Pitt, B. Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. The TREND (Trial on Reversing ENdothelial Dysfunction) Study. Circulation, 1996, 94, 258-265.
54. Antony, I., Lerebours, G., Nitenberg, A. Angiotensin-converting enzyme inhibition restores flow-dependent and cold pressor test-induced dilations in coronary arteries of hypertensive patients. Circulation, 1996, 94, 3115-3122.
55. Zhuo, J.L., Mendelsohn, F.A., Ohishi, M. Perindopril alters vascular angiotensin-converting enzyme, AT(1) receptor, and nitric oxide synthase expression in patients with coronary heart disease. Hypertension, 2002, 39, 634-638.
56. Schalkwijk, C.G., Smulders, R.A., Lambert, J., Donker, A.J., Stehouwer, C.D. ACE-inhibition modulates some endothelial functions in healthy subjects and in normotensive type 1 diabetic patients. Eur. J. Clin. Invest., 2000, 30, 853-860.
57. Gasic, S., Wagner, O.F., Fasching, P., Ludwig, C., Veitl, M., Kapiotis, S., Jilma, B. Fosinopril decreases levels of soluble vascular cell adhesion molecule-1 in borderline hypertensive type II diabetic patients with microalbuminuria. Am. J. Hypertens., 1999, 12, 217-222.
58. Kingwell, B.A., Waddell, T.K., Medley, T.L., Cameron, J.D., Dart, A.M. Large artery stiffness predicts ischemic threshold in patients with coronary artery disease. J. Am. Coll. Cardiol., 2002, 40, 773-779.
59. Thybo, N.K., Stephens, N., Cooper, A., Aalkjaer, C., Heagerty, A.M., Mulvany, M.J. Effect of antihypertensive treatment on small arteries of patients with previously untreated essential hypertension. Hypertension, 1995, 25, 474-481.
60. Schwartzkopff, B., Brehm, M., Mundhenke, M., Strauer, B.E. Repair of coronary arterioles after treatment with perindopril in hypertensive heart disease. Hypertension, 2000, 36, 220-225.
61. Lonn, E., Yusuf, S., Dzavik, V., Doris, C., Yi, Q., Smith, S., Moore-Cox, A., Bosch, J., Riley, W., Teo, K. Effects of ramipril and vitamin E on atherosclerosis: the study to evaluate carotid ultrasound changes in patients treated with ramipril and vitamin E (SECURE). Circulation, 2001, 103, 919-925.
62. Hosomi, N., Mizushige, K., Ohyama, H., Takahashi, T., Kitadai, M., Hatanaka, Y., Matsuo, H., Kohno, M., Koziol, J.A. Angiotensin-converting enzyme inhibition with enalapril slows progressive intima-media thickening of the common carotid artery in patients with non-insulin-dependent diabetes mellitus. Stroke, 2001, 32, 1539-1545.
63. Teo, K.K., Burton, J.R., Buller, C.E., Plante, S., Catellier, D., Tymchak, W., Dzavik, V., Taylor, D., Yokoyama, S., Montague, T.J. Long-term effects of cholesterol lowering and angiotensin-converting enzyme inhibition on coronary atherosclerosis: The Simvastatin/Enalapril Coronary Atherosclerosis Trial (SCAT). Circulation, 2000, 102, 1748-1754.
64. MacMahon, S., Sharpe, N., Gamble, G., Clague, A., Mhurchu, C.N., Clark, T., Hart, H., Scott, J., White, H. Randomized, placebo-controlled trial of the angiotensin-converting enzyme inhibitor, ramipril, in patients with coronary or other occlusive arterial disease. PART-2 Collaborative Research Group. Prevention of Atherosclerosis with Ramipril. J. Am. Coll. Cardiol., 2000, 36, 438-443.
65. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. Lancet, 2000, 355, 253-259.
66. Hansson, L., Lindholm, L.H., Niskanen, L., Lanke, J., Hedner, T., Niklason, A., Luomanmaki, K., Dahlof, B., de Faire, U., Morlin, C., Karlberg, B.E., Wester, P.O., Bjorck, J.E. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: the Captopril Prevention Project (CAPPP) randomised trial. Lancet, 1999, 353, 611-616.
67. Zuanetti, G., Latini, R., Maggioni, A.P., Franzosi, M., Santoro, L., Tognoni, G. Effect of the ACE inhibitor lisinopril on mortality in diabetic patients with acute myocardial infarction: data from the GISSI-3 study. Circulation, 1997, 96, 4239-4245.
68. Gustafsson, I., Torp-Pedersen, C., Kober, L., Gustafsson, F., Hildebrandt, P. Effect of the angiotensin-converting enzyme inhibitor trandolapril on mortality and morbidity in diabetic patients with left ventricular dysfunction after acute myocardial infarction. Trace Study Group. J. Am. Coll. Cardiol., 1999, 34, 83-89.
69. Estacio, R.O., Jeffers, B.W., Hiatt, W.R., Biggerstaff, S.L., Gifford, N., Schrier, R.W. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. N. Engl. J. Med., 1998, 338, 645-652.
70. Tatti, P., Pahor, M., Byington, R.P., Di Mauro, P., Guarisco, R., Strollo, G., Strollo, F. Outcome results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM. Diabet. Care, 1998, 21, 597-603.
71. Jandeleit-Dahm, K.A., Tikellis, C., Reid, C.M., Johnston, C.I., Cooper, M.E. Why blockade of the renin-angiotensin system reduces the incidence of new-onset diabetes. J. Hypertens., 2005, 23, 463-473.
72. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive, and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA, 2002, 288, 2981-2997.
73. Wing, L.M., Reid, C.M., Ryan, P., Beilin, L.J., Brown, M.A., Jennings, G.L., Johnston, C.I., McNeil, J.J., Macdonald, G.J., Marley, J.E., Morgan, T.O., West, M.J. A comparison of outcomes with angiotensin-converting - enzyme inhibitors and diuretics for hypertension in the elderly. N. Engl. J. Med., 2003, 348, 583-592.
74. Vermes, E., Ducharme, A., Bourassa, M.G., Lessard, M., White, M., Tardif, J.C. Enalapril reduces the incidence of diabetes in patients with chronic heart failure: insight from the Studies Of Left Ventricular Dysfunction (SOLVD). Circulation, 2003, 107, 1291-1296.
75. Julius, S., Kjeldsen, S.E., Brunner, H., Hansson, L., Platt, F., Ekman, S., Laragh, J.H., McInnes, G., Schork, A.M., Smith, B., Weber, M., Zanchetti, A. VALUE trial: Long-term blood pressure trends in 13,449 patients with hypertension and high cardiovascular risk. Am. J. Hypertens., 2003, 16, 544-548.
76. Pfeffer, M.A., Swedberg, K., Granger, C.B., Held, P., McMurray, J.J., Michelson, E.L., Olofsson, B., Ostergren, J., Yusuf, S., Pocock, S. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet, 2003, 362, 759-766.
77. Pfeffer, M.A., Braunwald, E., Moye, L.A., Basta, L., Brown, E.J. Jr., Cuddy, T.E., Davis, B.R., Geltman, E.M., Goldman, S., Flaker, G.C. et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE Investigators. N. Engl. J. Med., 1992, 327, 669-677.
78. Kober, L., Torp-Pedersen, C., Carlsen, J.E., Bagger, H., Eliasen, P., Lyngborg, K., Videbaek, J., Cole, D.S., Auclert, L., Pauly, N.C. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group. N. Engl. J. Med., 1995, 333, 1670-1676.
79. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Lancet, 1993, 342, 821-828.
80. Ambrosioni, E., Borghi, C., Magnani, B. The effect of the angiotensin-converting-enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. The Survival of Myocardial Infarction Long-Term Evaluation (SMILE) Study Investigators. N. Engl. J. Med., 1995, 332, 80-85.
81. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. N. Engl. J. Med., 1991, 325, 293-302.
82. Swedberg, K., Held, P., Kjekshus, J., Rasmussen, K., Ryden, L., Wedel, H. Effects of the early administration of enalapril on mortality in patients with acute myocardial infarction. Results of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II). N. Engl. J. Med., 1992, 327, 678-684.
83. Oral captopril versus placebo among 13,634 patients with suspected acute myocardial infarction: interim report from the Chinese Cardiac Study (CCS-1). Lancet, 1995, 345, 686-687.
84. ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group. Lancet, 1995, 345, 669-685.
85. GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Gruppo Italiano per lo Studio della Sopravvivenza nell'infarto Miocardico. Lancet, 1994, 343, 1115-1122.
86. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet, 2001, 358, 1033-1041.
87. Pitt, B., O'Neill, B., Feldman, R., Ferrari, R., Schwartz, L., Mudra, H., Bass, T., Pepine, C., Texter, M., Haber, H., Uprichard, A., Cashin-Hemphill, L., Lees, R.S. The QUinapril Ischemic Event Trial (QUIET): evaluation of chronic ACE inhibitor therapy in patients with ischemic heart disease and preserved left ventricular function. Am. J. Cardiol., 2001, 87, 1058-1063.
88. Fox, K.M. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet, 2003, 362, 782-788.
89. Braunwald, E., Domanski, M.J., Fowler, S.E., Geller, N.L., Gersh, B.J., Hsia, J., Pfeffer, M.A., Rice, M.M., Rosenberg, Y.D., Rouleau, J.L. Angiotensin-converting-enzyme inhibition in stable coronary artery disease. N. Engl. J. Med., 2004, 351, 2058-2068.
90. Lee, R.T. The PEACE Study: Limiting the Role of Angiotensin-converting Enzyme Inhibitors in Stable Coronary Artery Disease. Curr. Atheroscler. Rep., 2005, 7, 211-212.
91. Lindholm, L.H., Ibsen, H., Dahlof, B., Devereux, R.B., Beevers, G., de Faire, U., Fyhrquist, F., Julius, S., Kjeldsen, S.E., Kristiansson, K., Lederballe-Pedersen, O., Nieminen, M.S., Omvik, P., Oparil, S., Wedel, H., Aurup, P., Edelman, J., Snapinn, S. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet, 2002, 359, 1004-1010.
92. Julius, S., Kjeldsen, S.E., Weber, M., Brunner, H.R., Ekman, S., Hansson, L., Hua, T., Laragh, J., McInnes, G.T., Mitchell, L., Plat, F., Schork, A., Smith, B., Zanchetti, A. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet, 2004, 363, 2022-2031.
93. Brenner, B.M., Cooper, M.E., de Zeeuw, D., Keane, W.F., Mitch, W.E., Parving, H.H., Remuzzi, G., Snapinn, S.M., Zhang, Z., Shahinfar, S. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N. Engl. J. Med., 2001, 345, 861-869.
94. Lewis, E.J., Hunsicker, L.G., Clarke, W.R., Berl, T., Pohl, M.A., Lewis, J.B., Ritz, E., Atkins, R.C., Rohde, R., Raz, I. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N. Engl. J. Med., 2001, 345, 851-860.
95. Parving, H.H., Lehnert, H., Brochner-Mortensen, J., Gomis, R., Andersen, S., Arner, P. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N. Engl. J. Med., 2001, 345, 870-878.
96. Fitchett, D. Have angiotensin receptor blockers lived up to expectations? Can. J. Cardiol., 2005, 21, 569-575.
97. Sleight, P. The ONTARGET/TRANSCEND Trial Programme: baseline data. Acta Diabetol., 2005, 42 (Suppl. 1), S50-56.
98. Wei, M., Gaskill, S.P., Haffner, S.M., Stern, M.P. Effects of diabetes and level of glycemia on all-cause and cardiovascular mortality. The San Antonio Heart Study. Diabet. Care, 1998, 21, 1167-1172.